PARIS--(BUSINESS WIRE)--Regulatory News: ExonHit Therapeutics (Paris:ALEHT) (Alternext: ALEHT) announced today the termination of the Combination Agreement for the acquisition of RedPath Integrated Pathology, Inc. Following Highmark’s recent decision to limit coverage of RedPath PathFinderTG® family of tests to the Pancreatic cancer test only (https://www.highmarkmedicareservices.com/policy/mac-ab/l31144.html), the two companies were unable to agree on revised financial terms and conditions.
